BMS To Pay $2.1M To Settle FTC's Plavix Claims
Bristol-Myers Squibb Co. has agreed to fork over $2.1 million to settle allegations by the U.S. Federal Trade Commission that the drugmaker issued misleading statements about a proposed Plavix patent deal...To view the full article, register now.
Already a subscriber? Click here to view full article